Search

Your search keyword '"Mallant-Hent, Rosalie C."' showing total 44 results
Start Over Author "Mallant-Hent, Rosalie C." Language english
44 results on '"Mallant-Hent, Rosalie C."'

1. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial

Author

van Linschoten, Reinier C. A., Jansen, Fenna M., Pauwels, Renske W. M., Smits, Lisa J. T., Atsma, Femke, Kievit, Wietske, de Jong, Dirk J., de Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G. L., Gisbertz, Ingrid A. M., Wolfhagen, Frank H. J., Römkens, Tessa E. H., Lutgens, Maurice W. M. D., van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G. V. M., de Boer, Nanne K., Mallant-Hent, Rosalie C., ter Borg, Pieter C. J., van der Meulen-de Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C. I. T. L., van der Woude, C. Janneke, and Hoentjen, Frank

Published
2024
Full Text
View/download PDF

2. Computer-aided diagnosis improves characterization of Barrett’s neoplasia by general endoscopists (with video)

Author

Alkhalaf, Alaa, Herrero, Lorenza Alvarez, Baldaque-Silva, Francisco, Barret, Maximilien, Bergman, Jacques J., Beyna, Torsten, Bisschops, Raf, Boers, Tim G., Curvers, Wouter, Deprez, Pierre H., Duits, Lucas C., Elbe, Peter, Esteban, Jose Miguel, Falk, Gary W., Fockens, Kiki N., Ginsberg, Gregory G., de Groof, Albert J., Haidry, Rehan, Houben, Martin H., Infantolino, Anthony, Iyer, Prasad G., Jong, Martijn, Jonge, Pieter-Jan de, Jukema, Jelmer B., Koch, Arjun, Komanduri, Srinadh, Konda, Vani, Kusters, Koen C., Leclerq, Philippe, Leggett, Cadman L., Lightdale, Charles J., Mallant-Hent, Rosalie C., Villarejo, Guiomar Moral, Fernández-Sordo, Jacobo Ortiz, Pech, Oliver, Penman, Ian, Pouw, Roos E., van der Putten, Joost A., Ragunath, Krish, Scholten, Pieter, Seewald, Stefan, Sethi, Amritha, Smith, Michael S., van der Sommen, Fons, Trindade, Arvind, Wani, Sachin, Waxman, Irving, Westerhof, Jessie, Weusten, Bas L., de With, Peter H., Wolfsen, Herbert C., Kusters, Carolus H.J., Jong, Martijn R., Boers, Tim, Weusten, Bas L.A.M., Houben, Martin H.M.G., Nagengast, Wouter B., Mallant-Hent, Rosalie, Silva, Francisco Baldaque, Ortiz Fernández-Sordo, Jacobo, Moral Villarejo, Guiomar, Montazeri, Nahid S.M., der Sommen, Fons van, and de Groof, A. Jeroen

Published
2024
Full Text
View/download PDF

3. The use of a real-time computer-aided detection system for visible lesions in the Barrett’s esophagus during live endoscopic procedures: a pilot study (with video)

Author

Alkhalaf, Alaa, Herrero, Lorenza Alvarez, Baldaque-Silva, Francisco, Barret, Maximilien, Bergman, Jacques J., Beyna, Torsten, Boers, Tim G., Elbe, Peter, Fockens, Kiki N., de Groof, Albert J., Houben, Martin H., Jong, Martijn, Jukema, Jelmer B., Kusters, Koen C., Mallant-Hent, Rosalie C., Villarejo, Guiomar Moral, Nagengast, Wouter, Fernández-Sordo, Jacobo Ortiz, Pech, Oliver, Pouw, Roos E., van der Putten, Joost A., Ragunath, Krish, Scholten, Pieter, Seewald, Stefan, der Sommen, Fons van, Westerhof, Jessie, Weusten, Bas L., de With, Peter H., Jong, Martijn R., Boers, Tim, Kusters, Carolus H.J., Duits, Lucas C., van der Sommen, Fons, and de Groof, A. Jeroen

Published
2024
Full Text
View/download PDF

4. A deep learning system for detection of early Barrett's neoplasia: a model development and validation study

Author

Alkhalaf, Alaa, Alvarez Herrero, Lorenza, Baldaque-Silva, Francisco, Barret, Maximilien, Bergman, Jacques J, Beyna, Torsten, Bisschops, Raf, Boers, Tim G, Curvers, Wouter, Deprez, Pierre H, Duits, Lucas C, Elbe, Peter, Esteban, Jose M, Falk, Gary W, Fockens, Kiki N, Ganguly, Eric, Ginsberg, Gregory G, de Groof, Albert J, Haidry, Rehan, Houben, Martin H, Infantolino, Anthony, Iyer, Prasad G, Jong, Martijn R, De Jonge, Pieter-Jan, Jukema, Jelmer B, Koch, Arjun K, Komanduri, Srinadh, Konda, Vani, Kusters, Carolus H J, Leclercq, Philippe, Leggett, Cadman L, Lemmers, Arnaud, Lightdale, Charles J, Mallant-Hent, Rosalie C, Moral Villarejo, Guiomar, Muthusamy, V Raman, Nagengast, Wouter, Ortiz Fernández-Sordo, Jacobo, Pech, Oliver, Penman, Ian, Pleskow, Douglas K, Pouw, Roos E, van der Putten, Joost A, Ragunath, Krish, Scholten, Pieter, Seewald, Stefan, Sethi, Amritha, Smith, Michael S, Van der Sommen, Fons, Trindade, Arvind, Wani, Sachin, Waxman, Irving, Westerhof, Jessie, Weusten, Bas L, de With, Peter H N, Wolfsen, Herbert C, Fockens, K N, Jong, M R, Jukema, J B, Boers, T G W, Kusters, C H J, van der Putten, J A, Pouw, R E, Duits, L C, Montazeri, N S M, van Munster, S N, Weusten, B L A M, Alvarez Herrero, L, Houben, M H M G, Nagengast, W B, Westerhof, J, Alkhalaf, A, Mallant-Hent, R C, Scholten, P, Ragunath, K, Seewald, S, Elbe, P, Baldaque-Silva, F, Barret, M, Ortiz Fernández-Sordo, J, Villarejo, G Moral, Pech, O, Beyna, T, van der Sommen, F, de With, P H, de Groof, A J, and Bergman, J J

Published
2023
Full Text
View/download PDF

5. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial

Author

van Noord, Desirée, Hoekstra, Jildou, Kamphuis, Johannes T., Gorter, Moniek H.P., van Esch, Aura A.J., van Linschoten, Reinier C A, Jansen, Fenna M, Pauwels, Renske W M, Smits, Lisa J T, Atsma, Femke, Kievit, Wietske, de Jong, Dirk J, de Vries, Annemarie C, Boekema, Paul J, West, Rachel L, Bodelier, Alexander G L, Gisbertz, Ingrid A M, Wolfhagen, Frank H J, Römkens, Tessa E H, Lutgens, Maurice W M D, van Bodegraven, Adriaan A, Oldenburg, Bas, Pierik, Marieke J, Russel, Maurice G V M, de Boer, Nanne K, Mallant-Hent, Rosalie C, ter Borg, Pieter C J, van der Meulen-de Jong, Andrea E, Jansen, Jeroen M, Jansen, Sita V, Tan, Adrianus C I T L, van der Woude, C Janneke, and Hoentjen, Frank

Published
2023
Full Text
View/download PDF

9. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.

Author

Jansen, Fenna M, Linschoten, Reinier C A van, Kievit, Wietske, Smits, Lisa J T, Pauwels, Renske W M, Jong, Dirk J de, Vries, Annemarie C de, Boekema, Paul J, West, Rachel L, Bodelier, Alexander G L, Gisbertz, Ingrid A M, Wolfhagen, Frank H J, Römkens, Tessa E H, Lutgens, Maurice W M D, Bodegraven, Adriaan A van, Oldenburg, Bas, Pierik, Marieke J, Russel, Maurice G V M, Boer, Nanne K de, and Mallant-Hent, Rosalie C

Abstract

Background and Aims We aimed to assess cost-effectiveness of increasing adalimumab dose intervals compared to the conventional dosing interval in patients with Crohn's disease [CD] in stable clinical and biochemical remission. Design We conducted a pragmatic, open-label, randomized controlled non-inferiority trial, comparing increased adalimumab intervals with the 2-weekly interval in adult CD patients in clinical remission. Quality of life was measured with the EQ-5D-5L. Costs were measured from a societal perspective. Results are shown as differences and incremental net monetary benefit [iNMB] at relevant willingness to accept [WTA] levels. Results We randomized 174 patients to the intervention [ n  = 113] and control [ n  = 61] groups. No difference was found in utility (difference: −0.017, 95% confidence interval [−0.044; 0.004]) and total costs (−€943, [−€2226; €1367]) over the 48-week study period between the two groups. Medication costs per patient were lower (−€2545, [−€2780; −€2192]) in the intervention group, but non-medication healthcare (+€474, [+€149; +€952]) and patient costs (+€365 [+€92; €1058]) were higher. Cost–utility analysis showed that the iNMB was €594 [−€2099; €2050], €69 [−€2908; €1965] and −€455 [−€4,096; €1984] at WTA levels of €20 000, €50 000 and €80 000, respectively. Increasing adalimumab dose intervals was more likely to be cost-effective at WTA levels below €53 960 per quality-adjusted life year. Above €53 960 continuing the conventional dose interval was more likely to be cost-effective. Conclusion When the loss of a quality-adjusted life year is valued at less than €53 960, increasing the adalimumab dose interval is a cost-effective strategy in CD patients in stable clinical and biochemical remission. Clinical Trial Registration Number ClinicalTrials.gov , number NCT03172377. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice

Author

Curvers, Wouter L., van Vilsteren, Frederike G., Baak, Lubertus C., Böhmer, Clarisse, Mallant-Hent, Rosalie C., Naber, Anton H., van Oijen, Arnout, Ponsioen, Cyriel Y., Scholten, Pieter, Schenk, Ed, Schoon, Erik, Seldenrijk, Cees A., Meijer, Gerrit A., Kate, Fiebo J.ten, and Bergman, Jacques J.

Published
2011
Full Text
View/download PDF

13. Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round

Author

Stegeman Inge, de Wijkerslooth Thomas R, Mallant-Hent Rosalie C, de Groot Karin, Stroobants An K, Fockens Paul, Mundt Marco, Bossuyt Patrick MM, and Dekker Evelien

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Colorectal cancer (CRC) is the most common cancer in Europe with a mortality rate of almost 50%. The prognosis of patients is largely determined by the clinical and pathological stage at the time of diagnosis. Population screening has been shown to reduce CRC-related mortality rate. Most screening programs worldwide rely on fecal immunochemical testing (FIT). The effectiveness of a FIT screening program is not only influenced by initial participation rate, but also by program adherence during consecutive screening rounds. We aim to evaluate the participation rate in and yield of a third CRC screening round using FIT. Methods and design Four years after the first screening round and two years after the second round, a total number of approximately 11,000 average risk individuals (50 to 75 years of age) will be invited to participate in a third round of FIT-based CRC screening. We will select individuals in the same target area as in the previous screening rounds, using the electronic database of the regional municipal administration registrations. We will invite all FIT-negatives and all non-participants in previous screening rounds, as well as eligible first time invitees who have moved into the area or have become 50 years of age. FITs will be analyzed in the special technique laboratory of the Academic Medical Center of the University of Amsterdam. All FIT-positives will be invited for a consultation at the outpatient clinic. In the absence of contra-indications, a colonoscopy will follow at the Academic Medical Center or at the Flevohospital. The primary outcome measures are the participation rate, defined as the proportion of invitees that return a FIT in this third round of FIT-screening, and the diagnostic yield of the program. Implications This study will provide precise data on the participation in later FIT screening rounds. This enables to estimate the effectiveness of CRC screening programs that rely on repeated FIT- screening, such as the one that will be implemented in the Netherlands in 2013.

Published
2012
Full Text
View/download PDF

14. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.

Author

Kanis, Shannon Linda, Modderman, Sanne, Escher, Johanna C., Erler, Nicole, Beukers, Ruud, de Boer, Nanne, Bodelier, Alexander, Depla, Annekatrien C. T. M., Dijkstra, Gerard, van Dijk, Anne-Baue Ruth Margaretha, Gilissen, Lennard, Hoentjen, Frank, Jansen, Jeroen M., Kuyvenhoven, Johan, Mahmmod, Nofel, Mallant-Hent, Rosalie C., van der Meulen-de, Andrea E., Noruzi, Anahita, Oldenburg, Bas, and Oostenbrug, Liekele E.

Subjects
INFLAMMATORY bowel diseases, MOTHER-child relationship, IMMUNIZATION of children, TYPE 1 diabetes, SMALL for gestational age, LOW birth weight, PEDIATRIC gastroenterology
Published
2021
Full Text
View/download PDF

15. The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019)

Author

Gardenbroek, Tjibbe J., Pinkney, Thomas D., Sahami, Saloomeh, Morton, Dion G., Buskens, Christianne J., Ponsioen, Cyriel Y., Tanis, Pieter J., Löwenberg, Mark, van den Brink, Gijs R., Broeders, Ivo A. M. J., Pullens, Hendrikus J. M., Pullens, Paul H. J. M., Seerden, Tom, Boom, Maarten J., Mallant-Hent, Rosalie C., Pierik, Robert E. G. J. M., Vecht, Juda, Sosef, Meindert N., van Nunen, Annick B., van Wagensveld, Bart A., Stokkers, Pieter C. F., Gerhards, Michael F., Jansen, Jeroen M., Acherman, Yair, Depla, Annekatrien C. T. M., Mannaerts, Guido H. H., West, Rachel, Iqbal, Tariq, Pathmakanthan, Shrikanth, Howard, Rebecca, Magill, Laura, Singh, Baljit, Oo, Ye H., Htun Oo, Ye, Negpodiev, Dmitri, Dijkgraaf, Marcel G. W., D'Haens, Geert R. A. M., Bemelman, Willem A., Other departments, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Gastroenterology and Hepatology, AII - Amsterdam institute for Infection and Immunity, and Clinical Research Unit

Subjects
medicine.medical_specialty, Colectomies, business.industry, Standard treatment, General Medicine, medicine.disease, Ulcerative colitis, Inflammatory bowel disease, Surgery, law.invention, Clinical trial, Study Protocol, Randomized controlled trial, law, Multicenter trial, Medicine, Appendectomy, Disease course, business, Prospective cohort study
Abstract

Background: Over the past 20 years evidence has accumulated confirming the immunomodulatory role of the appendix in ulcerative colitis (UC). This led to the idea that appendectomy might alter the clinical course of established UC. The objective of this body of research is to evaluate the short-term and medium-term efficacy of appendectomy to maintain remission in patients with UC, and to establish the acceptability and cost-effectiveness of the intervention compared to standard treatment. Methods/Design: These paired phase III multicenter prospective randomised studies will include patients over 18 years of age with an established diagnosis of ulcerative colitis and a disease relapse within 12 months prior to randomisation. Patients need to have been medically treated until complete clinical (Mayo score

Published
2015

16. Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.

Author

Timmer, Margriet R., Martinez, Pierre, Lau, Chiu T., Westra, Wytske M., Calpe, Silvia, Rygiel, Agnieszka M., Rosmolen, Wilda D., Meijer, Sybren L., ten Kate, Fiebo J. W., Dijkgraaf, Marcel G. W., Mallant-Hent, Rosalie C., Naber, Anton H. J., van Oijen, Arnoud H. A. M., Baak, Lubbertus C., Scholten, Pieter, Böhmer, Clarisse J. M., Fockens, Paul, Maley, Carlo C., Graham, Trevor A., and Bergman, Jacques J. G. H. M.

Subjects
BARRETT'S esophagus, GENETIC markers, CANCER risk factors, DISEASE progression, ENDOSCOPY, DIAGNOSIS, THERAPEUTICS
Published
2016
Full Text
View/download PDF

20. Su1923 The Amsterdam ReBus Progressor Cohort: Identification of 153 Barrett's Surveillance Patients Who Progressed to Early Neoplasia and 1,098 Non-Progressor Patients

Author

Duits, Lucas C., Gonzalez, Angela Bureo, Boerwinkel, David F., Ten Kate, Fiebo T., Offerhaus, Johan, Meijer, Sybren L., Visser, Mike, Seldenrijk, Cees A., Krishnadath, Kausilia K., Schoon, Erik J., Weusten, Bas L., Mallant-Hent, Rosalie C., Pouw, Roos E., and Bergman, Jacques J.

Published
2015
Full Text
View/download PDF

24. 164 A FISH Biomarker Panel for the Prediction of High-grade Dysplasia and Adenocarcinoma in Non-Dysplastic Barrett's Esophagus; Results From a Long-Term Prospective Cohort Study

Author

Timmer, Margriet R., Lau, Chiu Ting, Rosmolen, Wilda, Meijer, Sybren L., Dijkgraaf, Marcel G., Mallant-Hent, Rosalie C., Naber, Anton H., Van Oijen, Arnoud H., Baak, Lubbertus C., Scholten, Pieter, BöHmer, Clarisse, Fockens, Paul, Bergman, Jacques J., and Krishnadath, Kausilia K.

Published
2014
Full Text
View/download PDF

29. Validation of the Prague C&M classification of Barrett's esophagus in clinical practice.

Author

Herrero, Lorenza Alvarez, Curvers, Wouter L., Van Vilsteren, Frederike G. I., Wolfsen, Herbert, Ragunath, Krish, Wong Kee Song, Louis-Michel, Mallant-Hent, Rosalie C., Van Oijen, Arnoud, Scholten, Pieter, Schoon, Erik J., Schenk, Ed B. E., Weusten, Bas L. A. M., and Bergman, Jacques G. H. M.

Subjects
BARRETT'S esophagus, ESOPHAGEAL cancer, ENDOSCOPY, CLINICAL trials, PATHOLOGY
Abstract

Background and study aims: The Prague C&M classification for Barrett's esophagus has found widespread acceptance but has only been validated by Barrett's experts scoring video sequences. To date, validation has been lacking for its application in routine practice during real-time endoscopy. The aim of this study was to evaluate agreement between Barrett's experts and community hospital endoscopists when using this classification to describe Barrett's esophagus and hiatal hernia length during real-time endoscopy. Patients and methods: Patients underwent two consecutive endoscopies performed by different endoscopists. The study was performed in two cohorts: one cohort was seen by Barrett's experts and the other cohort by community hospital endoscopists. Landmarks were recorded according to the Prague classification. Outcomes were interobserver agreement (assessed with intraclass correlation coefficient [ICC]), absolute agreement, and relative agreement. Results: A total of 187 patients were included, with median extent of C3M5 (IQR C1-7 M4-9) for Barrett's esophagus and 3cm (IQR 2-5) for hiatal hernia length. ICC was 0.91 (95% confidence interval [CI] 0.88-0.93) for maximum length, 0.92 (95 %CI 0.90-0.94) for circumferential extent, and 0.59 (95 %CI 0.49-0.68) for hiatal hernia length. Absolute agreement within⩽1cm was 74% (95 %CI 68-80) for circumference, 68% (95 %CI 62-75) for length, and 63% (95 %CI 56- 70) for hiatal hernia length. Relative agreement was 91% for Barrett's esophagus and 80% for hiatal hernia length. Barrett's experts and community hospital endoscopists showed no differences in agreement. Shorter Barrett's segments (⩽5cm) had lower agreement compared with longer segments (>5cm). Conclusions: Agreement was good for Barrett's esophagus and reasonable for hiatal hernia length. These findings strengthen the value of the Prague C&M classification to describe Barrett's esophagus and hiatal hernia length. Although absolute agreement during real-time endoscopy was high, one should anticipate that Barrett's values may vary by 1-2cm between two endoscopies [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

31. Low-Grade Dysplasia in Barrett's Esophagus: Overdiagnosed and Underestimated.

Author

Curvers, Wouter L., ten Kate, Fiebo J., Krishnadath, Kausilia K., Visser, Mike, Elzer, Brenda, Baak, Lubertus C., Bohmer, Clarisse, Mallant-Hent, Rosalie C., van Oijen, Arnout, Naber, Anton H., Scholten, Pieter, Busch, Olivier R., Blaauwgeers, Harriët G. T., Meijer, Gerrit A., and Bergman, Jacques J. G. H. M.

Subjects
DYSPLASIA, BARRETT'S esophagus, HISTOPATHOLOGY, HOSPITALS, PATHOLOGISTS, CANCER, PATIENTS
Abstract

OBJECTIVES:Published data on the natural history of low-grade dysplasia (LGD) in Barrett's esophagus (BE) are inconsistent and difficult to interpret. We investigated the natural history of LGD in a large community-based cohort of BE patients after reviewing the original histological diagnosis by an expert panel of pathologists.METHODS:Histopathology reports of all patients diagnosed with LGD between 2000 and 2006 in six non-university hospitals were reviewed by two expert pathologists. This panel diagnosis was subsequently compared with the histological outcome during prospective endoscopic follow-up.RESULTS:A diagnosis of LGD was made in 147 patients. After pathology review, 85% of the patients were downstaged to non-dysplastic BE (NDBE) or to indefinite for dysplasia. In only 15% of the patients was the initial diagnosis LGD. Endoscopic follow-up was carried out in 83.6% of patients, with a mean follow-up of 51.1 months. For patients with a consensus diagnosis of LGD, the cumulative risk of progressing to high-grade dysplasia or carcinoma (HGD or Ca) was 85.0% in 109.1 months compared with 4.6% in 107.4 months for patients downstaged to NDBE (P<0.0001). The incidence rate of HGD or Ca was 13.4% per patient per year for patients in whom the diagnosis of LGD was confirmed. For patients downstaged to NDBE, the corresponding incidence rate was 0.49%.CONCLUSIONS:LGD in BE is an overdiagnosed and yet underestimated entity in general practice. Patients diagnosed with LGD should undergo an expert pathology review to purify this group. In case the diagnosis of LGD is confirmed, patients should undergo strict endoscopic follow-up or should be considered for endoscopic ablation therapy. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

32. Transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND-study).

Author

van den Broek, Frank J. C., de Graaf, Eelco J. R., Dijkgraaf, Marcel G. W., Reitsma, Johannes B., Haringsma, Jelle, Timmer, Robin, Weusten, Bas L. A. M., Gerhards, Michael F., Consten, Esther C. J., Schwartz, Matthijs P., Boom, Maarten J., Derksen, Erik J., Bijnen, A. Bart, Davids, Paul H. P., Hoff, Christiaan, van Dullemen, Hendrik M., N. Heine, G. Dimitri, van der Linde, Klaas, Jansen, Jeroen M., and Mallant-Hent, Rosalie C. H.

Subjects
RECTAL cancer, MICROSURGERY, ENDOSCOPIC surgery, ADENOMA, MUCOUS membranes
Abstract

Background: Recent non-randomized studies suggest that extended endoscopic mucosal resection (EMR) is equally effective in removing large rectal adenomas as transanal endoscopic microsurgery (TEM). If equally effective, EMR might be a more cost-effective approach as this strategy does not require expensive equipment, general anesthesia and hospital admission. Furthermore, EMR appears to be associated with fewer complications. The aim of this study is to compare the cost-effectiveness and cost-utility of TEM and EMR for the resection of large rectal adenomas. Methods/design: Multicenter randomized trial among 15 hospitals in the Netherlands. Patients with a rectal adenoma ≥ 3 cm, located between 1-15 cm ab ano, will be randomized to a TEM- or EMR-treatment strategy. For TEM, patients will be treated under general anesthesia, adenomas will be dissected en-bloc by a full-thickness excision, and patients will be admitted to the hospital. For EMR, no or conscious sedation is used, lesions will be resected through the submucosal plane in a piecemeal fashion, and patients will be discharged from the hospital. Residual adenoma that is visible during the first surveillance endoscopy at 3 months will be removed endoscopically in both treatment strategies and is considered as part of the primary treatment. Primary outcome measure is the proportion of patients with recurrence after 3 months. Secondary outcome measures are: 2) number of days not spent in hospital from initial treatment until 2 years afterwards; 3) major and minor morbidity; 4) disease specific and general quality of life; 5) anorectal function; 6) health care utilization and costs. A cost-effectiveness and cost-utility analysis of EMR against TEM for large rectal adenomas will be performed from a societal perspective with respectively the costs per recurrence free patient and the cost per quality adjusted life year as outcome measures. Based on comparable recurrence rates for TEM and EMR of 3.3% and considering an upper-limit of 10% for EMR to be non-inferior (beta-error 0.2 and one-sided alpha-error 0.05), 89 patients are needed per group. Discussion: The TREND study is the first randomized trial evaluating whether TEM or EMR is more cost-effective for the treatment of large rectal adenomas. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

36. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods.

Author

Linskens RK, Mallant-Hent RC, Groothuismink A, Bakker-Jonges LE, van de Merwe JP, Hooijkaas H, von Blomberg BME, Meuwissen SGM, Linskens, Ronald K, Mallant-Hent, Rosalie C, Groothuismink, Z M Anthonie, Bakker-Jonges, Liesbeth E, van de Merwe, Joop P, Hooijkaas, Herbert, von Blomberg, B Mary E, and Meuwissen, Stephan G M

Published
2002
Full Text
View/download PDF

40. 1070 A Multi-Centre Randomized Cross-Over Trial Comparing Endoscopic Tri-Modal Imaging (ETMI) With Standard Endoscopy (SE) for the Detection of Dysplasia in Barrett's Esophagus (BE) Patients With Confirmed LGD Performed in a Non-University Setting

Author

Curvers, Wouter L., van Vilsteren, Frederike G., Baak, Bert C., Bohmer, Clarisse, Mallant-Hent, Rosalie C., van Oijen, Arnoud H., Scholten, Pieter, Naber, Anton H., Schoon, Erik J., Schenk, Ed, Meijer, Gerrit A., ten Kate, Fiebo J., and Bergman, Jacques

Published
2010
Full Text
View/download PDF

41. S1164 Detailed Inspection of the Mucosal Morphology in Barrett's Esophagus By Narrow Band Imaging Has No Additional Value Over Inspection with High-Resolution Endoscopy: An International Inter-Observer Study Using Expert and Non-Expert Endoscopists

Author

Curvers, Wouter L., Böhmer, Clarisse J., Mallant-Hent, Rosalie C., Naber, Anton H., Ponsioen, Cyriel, Ragunath, Krish, Singh, Rajvinder, Wallace, Michael B., Wolfsen, Herbert C., Wong Kee Song, Louis-Michel, Lindeboom, Robert, Fockens, Paul, and Bergman, Jacques J.

Published
2008
Full Text
View/download PDF

42. The Amsterdam ReBus progressor cohort: identification of 165 Barrett's surveillance patients who progressed to early neoplasia and 723 nonprogressor patients.

Author

Duits, L C, Klaver, E, Gonzalez, A Bureo, Boerwinkel, D F, Kate, F J W ten, Offerhaus, G J A, Meijer, S L, Visser, M, Seldenrijk, C A, Krishnadath, K K, Schoon, E J, Weusten, Bas L A M, Mallant-Hent, Rosalie C, Pouw, Roos E, and Bergman, Jacques J G H M

Subjects
BARRETT'S esophagus, PATIENT selection, BIOMARKERS, ESOPHAGEAL cancer, DISEASE progression, ADENOCARCINOMA, CANCER research
Abstract

Patient selection is suboptimal in most studies focused on identifying biological markers for neoplastic progression in Barrett's esophagus (BE). This study aims to describe a stringently selected community-based case-control cohort of non-dysplastic BE (NDBE) patients who progressed to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) and BE patients who never progressed to be used for future biomarker studies. We identified all patients referred for endoscopic work-up of BE neoplasia at three tertiary referral centers for treatment of BE neoplasia between 2000 and 2013. We performed a detailed registration of any endoscopic surveillance history before neoplastic progression. Controls were selected from a retrospective BE surveillance registration in 10 community hospitals. A total of 887 patients were referred for endoscopic work-up of BE neoplasia. Based on predefined selection criteria, we identified 165 progressor patients (82% men; mean age 55 years ± 10.4) with a baseline endoscopy demonstrating NDBE > 2 years before neoplastic progression. Using the same predefined selection criteria, 723 nonprogressor patients (67% men; mean age 57 years ± 11.3) with >2 years of endoscopic surveillance were identified. Median length of the BE segment was 5 cm (IQR 4–7) in progressors and 4 cm (IQR 2–6) in controls. Median duration of surveillance was 89 months (IQR 54–139) in progressors and 76 months (IQR 47–116) in nonprogressors. Paraffin embedded biopsies are available for biomarker research in all patients. Ethical approval was obtained and material transfer agreements were signed with all 58 contributing pathology labs. This is the largest community-based case-control cohort of BE patients with and without progression to early neoplasia. The stringent selection criteria and the availability of paraffin embedded biopsy specimens make this a unique cohort for biomarker studies. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus.

Author

Martinez, Pierre, Timmer, Margriet R., Lau, Chiu T., Calpe, Silvia, Sancho-Serra, Maria del Carmen, Straub, Danielle, Baker, Ann-Marie, Meijer, Sybren L., Kate, Fiebo J. W. ten, Mallant-Hent, Rosalie C., Naber, Anton H. J., van Oijen, Arnoud H. A. M., Baak, Lubbertus C., Scholten, Pieter, Böhmer, Clarisse J. M., Fockens, Paul, Bergman, Jacques J. G. H. M., Maley, Carlo C., Graham, Trevor A., and Krishnadath, Kausilia K

Published
2016
Full Text
View/download PDF

44. Erratum to: The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019).

Author

Gardenbroek, Tjibbe J., Pinkney, Thomas D., Sahami, Saloomeh, Morton, Dion G., Buskens, Christianne J., Ponsioen, Cyriel Y., Tanis, Pieter J., Löwenberg, Mark, van den Brink, Gijs R., Broeders, Ivo A. M. J., Pullens, Hendrikus J. M., Seerden, Tom, Boom, Maarten J., Mallant-Hent, Rosalie C., Pierik, Robert E. G. J. M., Vecht, Juda, Sosef, Meindert N., van Nunen, Annick B., van Wagensveld, Bart A., and Stokkers, Pieter C. F.

Subjects
APPENDECTOMY, ULCERATIVE colitis, PILOT projects
Abstract

A correction to the article "The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019)" in the 2015 issue is presented.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results